Chinese pharma deals surge as pipeline hits 30% global share

Chinese pharmaceutical companies signed 81 cross-border transactions by the end of June, reaching roughly 80% of last year’s full-year deal volume. The accelerating pace of outbound licensing and partnerships was driven by demand from buyers in 20 countries and regions. The United States, the United Kingdom, France and Italy emerged as the primary destinations for these assets.

The surge in transaction activity is underpinned by a massive expansion in China's underlying drug development pipeline. The country now accounts for about 30% of all new therapies currently under development globally, securing its position as the second-largest innovation hub worldwide. "China develops 30 per cent of new therapies worldwide as it rises to the top tier in innovation efficiency," said Lan Gongtao, deputy director general of the Department of Drug Registration at the National Medical Products Administration.

The breadth of the current deal flow illustrates a diversification beyond China's traditional manufacturing capabilities. The 81 transactions recorded in the first half spanned 10 distinct therapeutic areas. Oncology, metabolic diseases, immunology and neurology represented the core focus of the capital deployment, according to Chinese state media reports on Monday. This spread indicates that foreign acquirers are finding viable clinical candidates across multiple high-value disease categories.

For global pharmaceutical executives and institutional investors, these figures confirm a structural shift in how multinational drugmakers source their pipelines. Western companies are facing patent cliffs and diminishing returns on internal research. Sourcing candidates from China offers a mechanism to acquire clinical assets at more efficient valuations. The fact that buyers from 20 different jurisdictions are participating points to a broad-based acceptance of Chinese clinical data and regulatory rigor, reducing the historical perceived risk of these assets.

If the first-half trajectory continues, the total number of deals for 2024 will easily eclipse last year's final count. This sustained momentum would solidify China's role not just as a primary market for drug sales, but as an indispensable engine of global biopharma research and dealmaking. Market participants should anticipate that any major Western pharmaceutical firm without a dedicated China-sourcing strategy is increasingly at a competitive disadvantage in replenishing its product portfolio.